Evotec Stock - Thursday’s technical picture and sector backdrop

Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 18:15 CET. Details in the imprint.

Evotec (DE0005664809) remains a closely watched German biotech name among retail investors. With no new company announcements on Thursday, attention turns to the latest chart signals and how the stock trades around short-term support zones, according to recent Tradegate and Xetra data.

What Thursday’s trading shows

On Thursday, Evotec shares most recently traded around EUR 4.70 on German venues, including Tradegate and Xetra, with only modest intraday fluctuation according to local quote overviews. The price level leaves the stock near the lower end of its 12-month range.

Market data from Xetra and Tradegate indicate relatively low turnover compared with peak crisis phases in 2023, pointing to a more muted trading environment. All told, volatility has eased, but the price still reflects the heavy drawdown seen after earlier profit warnings and governance issues.

Chart levels and technical tone

Based on recent quote histories, Evotec stock trades clearly below its former double-digit prices and also remains under typical long-term moving averages, such as the 200-day line, which market portals currently place well above the EUR 5 mark. This gap underlines the ongoing repair phase.

Shorter-term, traders watch whether the mid-EUR 4 band can act as a stabilizing support after repeated tests in recent weeks. Against this backdrop, any sustained move back toward EUR 5 would first need confirmation through higher volume and clearer momentum, which is not yet visible on Thursday.

The biotech sector backdrop

Thursday’s technical assessment also sits within a quieter week for European biotech, with no sector-wide catalysts like major FDA decisions or blockbuster M&A announcements hitting the tape. As a result, Evotec’s trading largely mirrors stock-specific sentiment rather than a broad industry swing.

In sector benchmarks, diversified pharma and biotech names in Europe have recently shown mixed performance, with some large caps edging up while more speculative research-platform companies remain subdued. For Evotec, this means the recovery path is driven by its own execution and balance-sheet confidence more than by a rising biotech tide.

How Evotec makes its money

Evotec builds its business around outsourced drug discovery and development services for pharmaceutical and biotech partners, spanning early-stage research, preclinical work and selected clinical development. The company runs a network of research sites and earns revenues primarily from service fees, milestones and potential royalties.[LAND]

Where the stock trades today

The shares of Evotec (DE0005664809) most recently traded on Xetra at EUR 4.73 as of 06/18/2026, 17:35 CET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.